Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:ELDN NASDAQ:IPSC NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.72-2.0%$10.16$3.39▼$16.00$180.42M0.93154,476 shs77,305 shsELDNEledon Pharmaceuticals$2.74-4.4%$2.69$2.32▼$5.54$164.07M0.4497,939 shs285,100 shsIPSCCentury Therapeutics$0.54-2.8%$0.52$0.34▼$1.83$46.82M1.78695,740 shs576,141 shsSAVACassava Sciences$3.45-3.5%$2.43$1.15▼$33.98$166.90M-0.981.74 million shs887,489 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.48%+7.53%+20.69%+188.66%+43.33%ELDNEledon Pharmaceuticals+0.70%+12.60%+5.54%-16.37%+9.16%IPSCCentury Therapeutics+8.18%+11.15%+10.03%-1.28%-64.17%SAVACassava Sciences-1.65%+13.69%+65.28%+71.63%-86.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.72-2.0%$10.16$3.39▼$16.00$180.42M0.93154,476 shs77,305 shsELDNEledon Pharmaceuticals$2.74-4.4%$2.69$2.32▼$5.54$164.07M0.4497,939 shs285,100 shsIPSCCentury Therapeutics$0.54-2.8%$0.52$0.34▼$1.83$46.82M1.78695,740 shs576,141 shsSAVACassava Sciences$3.45-3.5%$2.43$1.15▼$33.98$166.90M-0.981.74 million shs887,489 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics+4.48%+7.53%+20.69%+188.66%+43.33%ELDNEledon Pharmaceuticals+0.70%+12.60%+5.54%-16.37%+9.16%IPSCCentury Therapeutics+8.18%+11.15%+10.03%-1.28%-64.17%SAVACassava Sciences-1.65%+13.69%+65.28%+71.63%-86.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.80Moderate Buy$31.67130.81% UpsideELDNEledon Pharmaceuticals 2.40Hold$10.00265.63% UpsideIPSCCentury Therapeutics 2.60Moderate Buy$3.75594.44% UpsideSAVACassava Sciences 1.50Reduce$2.00-41.94% DownsideCurrent Analyst Ratings BreakdownLatest IPSC, AVTX, SAVA, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/29/2025AVTXAvalo TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025AVTXAvalo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ELDNEledon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025IPSCCentury TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SAVACassava SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/17/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $25.009/5/2025AVTXAvalo TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/5/2025AVTXAvalo TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025AVTXAvalo TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K410.04N/AN/A$12.80 per share1.07ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/AIPSCCentury Therapeutics$6.59M7.08N/AN/A$1.90 per share0.28SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-11.53%-6.94%11/4/2025 (Estimated)SAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/6/2025 (Estimated)Latest IPSC, AVTX, SAVA, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025IPSCCentury Therapeutics-$0.39N/AN/AN/AN/AN/A8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/14/2025Q2 2025IPSCCentury Therapeutics-$0.38-$0.38N/A-$0.38$0.03 millionN/A8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A12.4412.44ELDNEledon PharmaceuticalsN/A8.128.12IPSCCentury TherapeuticsN/A10.7210.72SAVACassava SciencesN/A2.432.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%ELDNEledon Pharmaceuticals56.77%IPSCCentury Therapeutics50.20%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%ELDNEledon Pharmaceuticals12.30%IPSCCentury Therapeutics5.00%SAVACassava Sciences2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4013.15 million13.12 millionNot OptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableIPSCCentury Therapeutics17086.39 million82.07 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableIPSC, AVTX, SAVA, and ELDN HeadlinesRecent News About These CompaniesLUCID CAPITAL MARKETS Initiates Coverage of Cassava Sciences (SAVA) with Buy Recommendation1 hour ago | msn.comCassava Sciences initiated with a Buy at Lucid CapitalOctober 6 at 1:17 PM | msn.comCassava Sciences (NASDAQ:SAVA) Insider Robert Christopher Cook Purchases 13,725 SharesOctober 3, 2025 | insidertrades.comCassava Sciences (NASDAQ:SAVA) Insider Buys $39,939.75 in StockOctober 2, 2025 | marketbeat.comCassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program WithdrawalSeptember 27, 2025 | finance.yahoo.comInvestors Purchase High Volume of Cassava Sciences Call Options (NASDAQ:SAVA)September 26, 2025 | americanbankingnews.comCassava Sciences Target of Unusually High Options Trading (NASDAQ:SAVA)September 24, 2025 | marketbeat.comRichard Barry Buys 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 24, 2025 | insidertrades.comGoldman Sachs Group Inc. Boosts Stake in Cassava Sciences, Inc. $SAVASeptember 24, 2025 | marketbeat.comCassava Boss Buys Big As Stock CollapsesSeptember 23, 2025 | finance.yahoo.comRichard Barry Acquires 7,172 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 23, 2025 | marketbeat.comInsider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 47,308 Shares of StockSeptember 23, 2025 | insidertrades.comRichard Barry Buys 47,308 Shares of Cassava Sciences (NASDAQ:SAVA) StockSeptember 22, 2025 | marketbeat.comCassava Sciences (NASDAQ:SAVA) CEO Richard Barry Acquires 190,633 SharesSeptember 22, 2025 | marketbeat.comCassava Sciences Releases New Corporate PresentationSeptember 8, 2025 | tipranks.comCassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA SupercomputersAugust 25, 2025 | thezimbabwemail.comTCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPSC, AVTX, SAVA, and ELDN Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$13.72 -0.28 (-2.00%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Eledon Pharmaceuticals NASDAQ:ELDN$2.74 -0.13 (-4.37%) As of 12:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Century Therapeutics NASDAQ:IPSC$0.54 -0.02 (-2.76%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Cassava Sciences NASDAQ:SAVA$3.44 -0.13 (-3.50%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
